SEC Form 4 · accession 0001493152-18-000655
ONCOSEC MEDICAL Inc · ONCS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Richard B Slansky
Officer — Chief Financial Officer
Period of report
Jan 12, 2018
Accepted (ET)
Jan 17, 2018 · 4:23 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001444307
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2,F1,F3 | $1.32 | Jan 12, 2018 | A | 100,000 | A | Jan 12, 2018 | Nov 4, 2027 | Common Stock | 100,000 | 347,500 | D |
Explanation of responses
- F1OncoSec's (ONCS) stock closing price was $1.32 on November 4, 2017.
- F2The Stock Options to purchase 100,000 shares of common stock of the issuer were approved by OncoSec's Board of Directors on November 4, 2017 ("Grant Date") and the contingency restriction was removed after OncoSec's Annual Stockholders Meeting held on January 12, 2018.
- F325% vested on January 12, 2018, and the remaining 75% are vesting in 36 equal monthly increments, which began on the first monthly anniversary of the Grant Date, pursuant to the OncoSec Medical Incorporated 2011 Stock Incentive Plan.